Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 35.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 302,536 shares of the biopharmaceutical company's stock after buying an additional 79,602 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.10% of Amicus Therapeutics worth $2,850,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. KBC Group NV raised its position in shares of Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 3,120 shares during the last quarter. Legacy Capital Group California Inc. increased its stake in Amicus Therapeutics by 20.2% during the 4th quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company's stock valued at $219,000 after purchasing an additional 3,900 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Amicus Therapeutics in the third quarter worth about $55,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Amicus Therapeutics by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company's stock worth $597,000 after buying an additional 6,314 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its holdings in shares of Amicus Therapeutics by 46.3% during the third quarter. Los Angeles Capital Management LLC now owns 20,474 shares of the biopharmaceutical company's stock valued at $219,000 after buying an additional 6,484 shares during the last quarter.
Amicus Therapeutics Stock Performance
FOLD traded down $0.07 during trading on Friday, hitting $9.01. The company's stock had a trading volume of 2,904,549 shares, compared to its average volume of 2,390,380. The business's 50 day simple moving average is $9.35 and its 200-day simple moving average is $10.10. The firm has a market cap of $2.77 billion, a PE ratio of -50.06, a P/E/G ratio of 1.51 and a beta of 0.69. Amicus Therapeutics, Inc. has a one year low of $8.55 and a one year high of $12.65. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on FOLD shares. Wells Fargo & Company lowered their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. Morgan Stanley reaffirmed an "equal weight" rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Cantor Fitzgerald restated an "overweight" rating and set a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Finally, StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Amicus Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $16.75.
Get Our Latest Stock Report on Amicus Therapeutics
About Amicus Therapeutics
(
Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
See Also
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
